louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03399201: The Effect of Anesthesia Type on Pulmonary Function
Official title: The Effect of General or Spinal Anesthesia on Pulmonary Function Tests in Geriatric Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anesthesia
Geriatric Patients
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2018-01-16
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Maximum age (years): 95
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The role of neuraxial anesthesia in preventing respiratory complications is a controversial in elderly patients. The aim of the study was to evaluate the benefits of neuraxial anesthesia on pulmonary function during post-operative term in geriatric patients undergoing to elective non-abdominal surgery.

Detailed description: Sixty elder patients will be randomly assigned to General anesthesia or Neuraxial anesthesia groups. Spirometry, will be performed at pre-operative and post-operative terms. Pulmonary function tests will be evaluated.

Eligibility criteria: Inclusion Criteria:

* 65 years of age
* Undergoing non-abdominal surgery under anesthesia in supine position

Exclusion Criteria:

* Pulmonary disease
* Hematological disease
* Undergoing Abdominal surgery
* Non-supine position during surgery
* Nicotine Abuse

Primary outcomes:
measure: The changes on forced vital capacity
timeFrame: At Preoperative, postoperative 2. hours, postoperative 24. hours
measure: The changes on forced expiratory volume in 1 s
timeFrame: At Preoperative, postoperative 2. hours, postoperative 24. hours
measure: The changes on mid-expiratory flow (MEF 25-75)
timeFrame: At Preoperative, postoperative 2. hours, postoperative 24. hours
measure: The changes on peak expiratory flow (PEF)
timeFrame: At Preoperative, postoperative 2. hours, postoperative 24. hours
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Gaziosmanpasa University Hospital
state: Merkez
Study officials:
affiliation: Associate Professor
name: Tuğba Karaman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05353101: Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
Official title: Efficiency and Safety of Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis: a Non-randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Vernal Keratoconjunctivitis
Cyclosporine 0.05% Eye Drops
Keywords: Cyclosporine 0.05% eye drops
Vernal Keratoconjunctivitis
Immunomodulator
Olopatadine Hydrochloride Eye Drops
Lead sponsor: Second Affiliated Hospital of Nanchang University
Sponsor class: OTHER
First posted: 2022-04-29
Enrollment: 48
Sex: ALL
Minimum age (years): 12
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.

Detailed description: Vernal keratoconjunctivitis (VKC) is an allergic disease that severely affects the eyesight of adolescents. Vernal keratoconjunctivitis (VKC) usually occurs in temperate regions such as the Mediterranean region, the Middle East, Africa, Central America, and the Indian subcontinent. In the EU an estimated 3.2 per 10,000 inhabitants (0.03%). It occurs repeatedly and mainly involves type I and type IV hypersensitivity. long-term standardized treatment is necessary. Therefore, this research aims to compare the readily available cyclosporine 0.05% eye drops and Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in developing regions of Asia (China, Jiangxi Province) for long-term drug use in VKC patients in developing countries provide evidence.

Eligibility criteria: Inclusion criteria

* patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning, stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;
* Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, Keratitis in some patients;
* No other medication history in recent 2 weeks;
* Patients have high compliance and are willing to take drugs on time and return to the clinic in time

Exclusion criteria:

* with other related immune diseases or other drug use history in recent 2 weeks;
* Patients with evident and severe organic diseases or mental diseases;
* Low compliance, unable to take drugs on time or fail to return to the clinic on time.

Primary outcomes:
measure: Changes of ocular signs
timeFrame: Day 0#7#15#30 and 60d
measure: Changes of self-conscious symptoms
timeFrame: Day 0#7#15#30 and 60d
Secondary outcomes:
Other outcomes:
Locations:
city: Nanchang
country: China
facility: the Second Affiliated Hospital of Nanchang University
state: Jiangxi
Study officials:
References:
Clinical trial NCT01932567: Electrical Impedance Tomography (EIT) and Physiotherapy
Official title: Effect of Physiotherapy Evaluated by Electrical Impedance Tomography
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiratory Disease
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2013-08-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: To compare the effect of different airway clearance techniques on lung ventilation by electrical impedance tomography.


Eligibility criteria: Inclusion Criteria:

* \>18 years old
* Surgery under anesthesia (PEP and incentive spirometry) or healthy subjects
* Intervention time before first bed lift
* Cooperative
* Can perform devices techniques correctly

Exclusion Criteria:

* Patients with pacemaker, implantable pumps or automatic implantable cardioverter defibrillator
* Patients with pulmonary disease (acute or chronic)
* Patients with cognitive problems
* Presence of patches or wounds in EIT belt zone placement
* Patients with initial pain \> 2/10
* Patients with severe obesity (BMI \> 35)

Primary outcomes:
measure: Regional lung ventilation measured by Electrical impedance tomography
timeFrame: Recording by electrical impedance tomography will be performed during 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Clinique universitaire Saint-Luc
city: Brussels
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
References:
Clinical trial NCT02647567: Caffeine Intake and Additive Effects on Cognition
Official title: Can Caffeine Intake Combined With Aerobic Exercise Leads to Cognitive Improvement and Psychomotor Performance in Trained Individuals?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Cognitive
Aerobic Exercise
Performance
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
First posted: 2016-01-06
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Caffeine is a methylxanthine commonly consumed by the population for their psychostimulant properties, and their intake when in moderate doses seem to produce positive effects on stress, mood and memory. So, understanding that a positive effect of aerobic exercise can be displayed also on cognition, as caffeine, when in proper proportions, the investigators do not know if the joining of the two strategies into a single activity would be able to promote additional effects enhancing cognitive processes related to memory, attention, and motor reaction time.

Detailed description: Determine if 500 mg of caffeine can generate additional effects to 30 minutes of aerobic exercise enhancing cognitive memory tasks (Rey Auditory Verbal Learning Test - RAVLT), attention (sustained attention span; working speed; Percentual of errors by confusion) and simple reaction time (SRT).

Eligibility criteria: Inclusion Criteria:

* Fighting men
* Low levels of consumption of caffeine daily

Exclusion Criteria:

* Use more than 400 mg caffeine day
* Mental diseases
* Cognitive deficits

Primary outcomes:
measure: Simple Reaction Time
timeFrame: Acute Change from Baseline Psychomotor test to 1 min after aerobic exercise, and after 30 min
measure: Rey Auditory Verbal Learning Test
timeFrame: Acute Change from Baseline Cognitive test to 1 min after aerobic exercise, and after 30 min
measure: Sustained Attention Test
timeFrame: Acute Change from Baseline Cognitive test to 1 min after aerobic exercise, and after 30 min
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Salgado de Oliveira University
name: Sérgio Machado, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00004767: Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Amino Acid Metabolism, Inborn Errors
Keywords: inborn errors of metabolism
rare disease
urea cycle disorder
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Johns Hopkins University
First posted: 2000-02-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.

Detailed description: PROTOCOL OUTLINE: This protocol describes several clinical studies of pharmacologic and dietary management in patients with urea cycle disorders.

Patients with carbamyl phosphate synthetase and ornithine transcarbamylase deficiency are treated with a low-protein diet, essential amino acids (for neonatal onset disease), caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and citrulline or arginine free base.

Patients with argininosuccinic acid synthetase deficiency are treated with a low-protein diet, caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and arginine free base.

Patients with argininosuccinic aciduria (AA) are treated with a low-protein diet, caloric supplementation, and arginine free base. (Discontinued 11/97) Any patient who develops hyperammonemia is treated with intravenous sodium benzoate, sodium phenylbutyrate, and arginine hydrochloride; benzoate and phenylbutyrate are not given to patients with AA.

If ammonium stabilizes at normal or near normal levels, intravenous medications are gradually replaced by oral medications. If there is no significant decrease in ammonium within 8 hours, patients begin hemodialysis.

Concurrent therapy with ondansetron, high caloric intake, and mannitol for elevated intracranial pressure is allowed. Dietary and intravenous nitrogen is prohibited. (Discontinued 11/97)

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

Urea cycle deficiency, i.e.: Carbamyl phosphate synthetase deficiency (CPSD) Ornithine transcarbamylase deficiency (OTCD) Argininosuccinic acid synthetase deficiency (ASD) Argininosuccinic aciduria (AA)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins University
name: Saul W. Brusilow
role: STUDY_CHAIR
References:
Clinical trial NCT02665767: Telementoring for Identifying the Appendix Using Telesonography
Official title: A Feasibility Study of Telementoring for Identifying the Appendix Using Smartphone-based Telesonography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Appendix, Ultrasonography
Keywords: Telesonography, Appendix
Lead sponsor: Hanyang University
Sponsor class: OTHER
First posted: 2016-01-28
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The investigators investigated the feasibility of the clinical application of novice-practitioner-performed/offsite-mentor-guided ultrasonography for identifying the appendix.

Detailed description: A randomized cross-over study was conducted using a telesonography system that can transmit the ultrasound images displayed on the ultrasound monitor(ultrasound sequence video) and images showing the practitioner's operations(background video) to a smartphone without any interruption in motion over a Long Term Evolution (LTE) network. Thirty novice practitioners were randomly assigned to two groups. The subjects in group A (n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert, whereas those in group B (n=15) performed the same procedure under mentoring by an offsite expert.

Each subject performed the procedure on three simulated patients. After a four-week interval, they performed the procedure again under the other type of mentoring. A total of 90 ultrasound examinations were performed in each scenario. The primary outcomes were the success rate for identifying the appendix and the time required to identify the appendix.

Eligibility criteria: Inclusion Criteria:

* Without any experience in ultrasonography

Exclusion Criteria:

* Subjects who do not want to participate
* Subjects who has eye pain or any eye problem
* Subjects who has wrist pain

Primary outcomes:
measure: Success rate
timeFrame: 8 months
Secondary outcomes:
measure: Time to identifying appendix
timeFrame: 8 months
Other outcomes:
Locations:
city: Guri-si
country: Korea, Republic of
facility: Hanyang University Guri Hospital
state: Gyeonggi-do
Study officials:
affiliation: Departement of Emergency Medicine, Hanyang University Guri Hospital
name: YOONJE LEE, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04168567: The Impact of Body Mass Index on the Endometrial Microbiome in IVF Treatments. Tampere Infertility Microbiome Project (TIMP).
Official title: A Protocol for a Prospective Study to Compare the Endometrial Microbiome in Patients With Body Mass Index Over 30 kg/m² Versus 20-25 kg/m².
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Keywords: Microbiome
Microbiota
Obesity
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2019-11-19
Enrollment: 91
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese and non-obese female with male-infertility

Brief summary: This study project is an observational trial involving 90 patients suffering from male type infertility. The patients are divided in two groups (45 patients per group) based on their body mass index (BMI). .

Detailed description: This study (Tampere Infertility Microbiome Project, TIMP) aims to clarify the differences in the endometrial, vaginal and anal microbiome variety between obese and healthy-weight patients. The first group will consist of patients with the body mass index (BMI) over 30 kg/m², while the second group will include patients with a healthy weight BMI 20-25 (under 26). The samples will be collected at the time of embryo transfer and analyzed in a laboratory specialing in next-geration sequencing (NGS) techniques.

Eligibility criteria: Inclusion Criteria:

* Patients with male infertility scheduled for IVF treatment and fresh embryo transfer
* Primary or secondary male-type infertility
* BMI over 30 kg/m² or between 20-25 kg/m² (under 26)
* Patient's willingness to participate

Exclusion Criteria:

* Patients with endometriosis or adenomyosis
* Use of antibiotics during IVF treatment or oocyte retrieval
* Technical diffuculties in embryo transfer or no embryos available for transfer

Primary outcomes:
measure: Microbiome variety between groups
timeFrame: through study completion, 1-2 years from the starting date
Secondary outcomes:
measure: Ongoing pregnancy rate
timeFrame: up to 2-3 months
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere University Hospital
Study officials:
affiliation: Tampere University Hospital
name: Katja Ahinko
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05139667: Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus
Official title: Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus ( A Randomized Controlled Clinical Trial With Immunohistochemical Analysis)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Oral Lichen Planus
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-12-01
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: treatment of oral lichen planus
Primary purpose: TREATMENT

Brief summary: tacrolimus has been widely used as an immunosuppressant. the objective of this study was to evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to investigate the effect of topical tacrolimus or corticosteroids on the expression of caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically analysis

Detailed description: thirty patients with erosive or atrophic OLP were randomly assigned into three equal groups to receive topical steroid ( triamcinolone acetonide 0.1%), four times per day ( Group 1), tacrolimus paste 0.1% four times per day ( Group 2) , and tacrolimus patch 2 times per day ( Group 3). all groups are given treatment for 8 weeks and 4 weeks follow up period without treatment. Photographs of the most severe lesion were taken ( marker lesion ) in each patient and analyzed for total ulcerative area (TUA), total atrophic area (TAA). patients were also assessed using clinical scores (CS) and visual analogue scale (VAS). pre treatment and post treatment specimens were immunohistochemically stained to detect expression of caspase-3.

Eligibility criteria: Inclusion Criteria:

* clinically and histologically proven painful bullous/erosive or atrophic forms of OLP

Exclusion Criteria:

* lichenoid lesions smoking systemic conditions pregnancy or breast feeding known hypersnstivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation

Primary outcomes:
measure: clinical score
timeFrame: change from baseline at 12 weeks
Secondary outcomes:
measure: caspase-3
timeFrame: change from base line at 8 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Noha Dawoud
Study officials:
References:
Clinical trial NCT04346667: Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
Official title: Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: SARS-CoV-2
Coronavirus Infection
Asymptomatic Condition
COVID-19
Lead sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department
Sponsor class: OTHER_GOV
Collaborators: name: Mayo Hospital Lahore
name: Services Institute of Medical Sciences, Pakistan
name: Pakistan Kidney and Liver Institute
name: Forman Christian College, Pakistan
name: Harvard School of Public Health (HSPH)
First posted: 2020-04-15
Enrollment: 125
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.


Eligibility criteria: Inclusion Criteria:

1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient
2. Age 20-50 years
3. BMI 18-28 kg/m2
4. Informed consent

Exclusion Criteria:

1. Symptoms: Cough, fever, shortness of breath
2. O2 saturation by pulse-oximeter below 94%
3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes
4. Arrhythmias and/or history of arrythmia
5. Psoriasis and/or history of psoriasis
6. Neuropathy or myopathy and/or history of these
7. Hypoglycemia and/or history of hypoglycemia
8. Pre-existing hepatic disease
9. Pre-existing renal disease
10. Use of antacids within 1 week
11. Use of antibiotics within 1 week
12. Pregnancy
13. RT-PCR performed \>3 days prior to enrollment

Primary outcomes:
measure: RT-PCR negative status
timeFrame: 6-7 days
Secondary outcomes:
measure: Progression of symptoms
timeFrame: 7 days
measure: Development of Symptoms
timeFrame: 7 days
measure: Adverse events
timeFrame: 7 days
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Expo Covid Center
state: Punjab
city: Lahore
country: Pakistan
facility: Mayo Hospital
state: Punjab
city: Lahore
country: Pakistan
facility: Pakistan Kidney and Liver Institute
state: Punjab
Study officials:
References:
Clinical trial NCT01360567: The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia
Official title: Taipei City Hospital, Taipei, Taiwan
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes
Hyperlipidemia
Keywords: green tea
EGCG
type 2 diabetes
hyperlipidemia
Lead sponsor: Taipei City Hospital
Sponsor class: OTHER_GOV
Collaborators: name: National Yang Ming Chiao Tung University
First posted: 2011-05-25
Enrollment: 102
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to examine whether the extract of green tea is effective on type 2 diabetes and hyperlipidemia.

Detailed description: Percent change Homa insulin resistance, cholesterol and triglycerol.

Eligibility criteria: Inclusion Criteria:

* Age 20--69 years old
* Type 2 diabetes for \> one year
* TG \>= 150 mg/dl or LDL \>= 100 mg/dl

Exclusion Criteria:

* GPT \> 80 mg/dl
* Creatinine \> 1.8 mg/dl
* Pregnancy
* AMI
* Stroke
* Operational or any not suitable patients diagnosis physician in charge

Primary outcomes:
measure: Percent change of HOMA insulin resistance and TG
timeFrame: 16 weeks
Secondary outcomes:
measure: Percent change of HbA1C and Cholesterol
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Chung-Hua Hsu
city: Taipei
country: Taiwan
facility: Taipei City Hospital
Study officials:
affiliation: Taipei City Hospital
name: Chung-Hua Hsu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008 Jun;27(3):363-70. doi: 10.1016/j.clnu.2008.03.007. Epub 2008 May 12.
citation: Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial. PLoS One. 2014 Mar 10;9(3):e91163. doi: 10.1371/journal.pone.0091163. eCollection 2014.